Sugi Predict

Sugi Predict / Targets / SLC5A7

SLC5A7

High affinity choline transporter 1 · Q9GZV3 · SLC5A7 on Sugi Atlas →

4,508 patent compounds predicted against SLC5A7, 2,576 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3862171 SCHEMBL3862171 0.44 9/20
SCHEMBL2452424 SCHEMBL2452424 0.41 9/20
SCHEMBL4784378 SCHEMBL4784378 0.45 8/20
SCHEMBL412066 SCHEMBL412066 0.41 7/20
SCHEMBL4511966 SCHEMBL4511966 0.53 6/20
SCHEMBL4498161 SCHEMBL4498161 0.56 5/20
SCHEMBL4372905 SCHEMBL4372905 0.55 5/20
SCHEMBL4688677 SCHEMBL4688677 0.47 5/20
SCHEMBL2551264 SCHEMBL2551264 0.41 5/20
SCHEMBL412251 SCHEMBL412251 0.40 5/20
SCHEMBL4488318 SCHEMBL4488318 0.52 4/20
SCHEMBL2815582 SCHEMBL2815582 0.47 4/20
SCHEMBL4683166 SCHEMBL4683166 0.46 4/20
SCHEMBL4687069 SCHEMBL4687069 0.46 4/20
SCHEMBL1633914 SCHEMBL1633914 0.42 4/20
SCHEMBL412341 SCHEMBL412341 0.41 4/20
SCHEMBL4497207 SCHEMBL4497207 0.61 3/20
SCHEMBL4933296 SCHEMBL4933296 0.60 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4666207) 0.57 3/20
SCHEMBL4512430 SCHEMBL4512430 0.54 3/20

Clinical trials — most relevant to SLC5A7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis PHASE2/PHASE3NOT_YET_RECRUITING
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease nanNOT_YET_RECRUITING
Choline to Improve Malnutrition and Enhance Cognition nanRECRUITING
Effect of Maternal Choline Intake on Choline Status and Health Biomarkers During Pregnancy and Lactation nanCOMPLETED
Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants nanCOMPLETED
Egg Intake, Metabolic Outcomes and Choline Levels nanRECRUITING
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) nanACTIVE_NOT_RECRUITING
Choline Dose Ranging in Postmenopausal Women nanCOMPLETED
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression nanCOMPLETED
Evaluation of Renal Function in Patients With Hyperthyroidism nanNOT_YET_RECRUITING
Clinical Utility of Breath Tests in GI nanCOMPLETED
Choline and Brain Functioning in Postmenopausal Women nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer nanUNKNOWN
Maternal Choline Supplementation and Offspring Cognition in Adolescence nanENROLLING_BY_INVITATION
18F-FDOPA PET in Neuroendocrine Tumours nanNO_LONGER_AVAILABLE
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation nanRECRUITING
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS nanCOMPLETED
Autonomic Function in Patients With COPD nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC5A7 binder may also engage these)

ProteinNameSimilarity
Q8UWF0 — 1.000 Q8UWF0 →
Q9JMD7 — 1.000 Q9JMD7 →
Q8BGY9 — 1.000 Q8BGY9 →
O02228 — 0.991 O02228 →
SLC5A11 Sodium/myo-inositol cotransporter 2 0.982 landscape →
P53790 — 0.982 P53790 →
A8WHP3 — 0.981 A8WHP3 →
A0PJK1 — 0.980 A0PJK1 →
P11170 — 0.980 P11170 →
Q3ZC26 — 0.980 Q3ZC26 →
Q2M3M2 — 0.978 Q2M3M2 →
Q9ET37 — 0.978 Q9ET37 →
SLC5A1 Sodium/glucose cotransporter 1 0.978 landscape →
Q5SWY8 — 0.977 Q5SWY8 →
D3ZIS0 — 0.977 D3ZIS0 →
Q9NY91 — 0.976 Q9NY91 →
Q8C3K6 — 0.976 Q8C3K6 →
Q91ZP4 — 0.976 Q91ZP4 →
A8I1B9 — 0.976 A8I1B9 →
P31636 — 0.975 P31636 →
P26429 — 0.975 P26429 →
P53791 — 0.975 P53791 →
Q8VDT1 — 0.974 Q8VDT1 →
Q8K0E3 — 0.974 Q8K0E3 →
Q9Z1F2 — 0.973 Q9Z1F2 →
Q28610 — 0.973 Q28610 →
Q9XT74 — 0.971 Q9XT74 →
P53793 — 0.971 P53793 →
Q9VE46 — 0.971 Q9VE46 →
F4KD71 — 0.971 F4KD71 →